NCT06631495

Brief Summary

The corresponding prevention strategies and treatment routes of HPV infection can be provided through investigating causes of death due to HPV infection and specialized diseases.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100,000

participants targeted

Target at P75+ for all trials

Timeline
17mo left

Started Oct 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress55%
Oct 2024Oct 2027

First Submitted

Initial submission to the registry

August 29, 2024

Completed
1 month until next milestone

Study Start

First participant enrolled

October 1, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 8, 2024

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2026

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2027

Last Updated

October 8, 2024

Status Verified

August 1, 2024

Enrollment Period

2 years

First QC Date

August 29, 2024

Last Update Submit

October 6, 2024

Conditions

HPV Infection

Outcome Measures

Primary Outcomes (1)

  • HR-HPV infection AND all-cause and diseases-specific mortality

    all-cause and diseases-specific mortality of HR-HPV infection

    one year

Secondary Outcomes (2)

  • time-period of HR-HPV infection AND all-cause and diseases-specific mortality

    one year

  • HR-HPV type AND all-cause and diseases-specific mortality

    one year

Study Arms (1)

HPV infection

patients with HPV infection

Other: Observation

Interventions

ObservationOTHER

not available-observation study

HPV infection

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Female participate in cervical cancer screening

You may qualify if:

  • Female participate in at least once cervical cancer screening with clear information of HPV DNA test results;
  • Having clear identification (ID number or others) that can be retrieved in the cause of death database.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking Union Medical College Hospital

Beijing, 100730, China

Location

MeSH Terms

Conditions

Papillomavirus Infections

Interventions

Observation

Condition Hierarchy (Ancestors)

Sexually Transmitted Diseases, ViralSexually Transmitted DiseasesCommunicable DiseasesInfectionsDNA Virus InfectionsVirus DiseasesTumor Virus InfectionsGenital DiseasesUrogenital DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Central Study Contacts

Li, doctor

CONTACT

13911988831lileigh@163.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

August 29, 2024

First Posted

October 8, 2024

Study Start

October 1, 2024

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

October 1, 2027

Last Updated

October 8, 2024

Record last verified: 2024-08

Locations

CN(1)